1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

USV chief on the metformin 'marathon' & shape of India's diabetes market

 
• By Anju Ghangurde

Prashant Tewari, managing director of the Indian generic firm USV is confident of the sustained dominance of oral medications in the diabetes segment in the country, even as new innovator therapies and strategic investments by foreign firms add to the competitive pressures.

Prashant Tewari, managing director of the Indian generic firm USV is confident of the sustained dominance of oral medications in the diabetes segment in the country, even as new innovator therapies and strategic investments by foreign firms add to the competitive pressures.

In a interview with Scrip, Mr Tewari, whose firm accounts for around 16% share of the oral anti-diabetes drugs (OADs) market in India and also co-markets Novartis' vildagliptin, underscored why making a dent in therapies like metformin was akin to ''climbing a mountain'' for entrants and that Sanofi's investment in

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Therapy Areas

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.